AFT Stock Overview
AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
AFT Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$3.14 |
| 52 Week High | NZ$3.92 |
| 52 Week Low | NZ$2.84 |
| Beta | 0.23 |
| 1 Month Change | 5.72% |
| 3 Month Change | -16.71% |
| 1 Year Change | -10.29% |
| 3 Year Change | -22.47% |
| 5 Year Change | 57.00% |
| Change since IPO | 1.29% |
Recent News & Updates
Recent updates
Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?
May 22
Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?
Oct 17Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?
May 23Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?
Dec 01We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise
Jul 30With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For
Jun 02Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?
Mar 20A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation
Feb 13
Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 23Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?
Jan 02Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?
Dec 12AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Nov 21Shareholder Returns
| AFT | NZ Pharmaceuticals | NZ Market | |
|---|---|---|---|
| 7D | -2.8% | -3.8% | -0.8% |
| 1Y | -10.3% | 32.1% | -4.5% |
Return vs Industry: AFT underperformed the NZ Pharmaceuticals industry which returned 32.1% over the past year.
Return vs Market: AFT underperformed the NZ Market which returned -4.5% over the past year.
Price Volatility
| AFT volatility | |
|---|---|
| AFT Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in NZ Market | 7.5% |
| 10% least volatile stocks in NZ Market | 2.4% |
Stable Share Price: AFT has not had significant price volatility in the past 3 months.
Volatility Over Time: AFT's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO |
|---|---|---|
| 1997 | 100 | Hartley Atkinson |
| Website |
|---|
| www.aftpharm.com |
AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, and supplements, as well as other products. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.
AFT Pharmaceuticals Limited Fundamentals Summary
| AFT fundamental statistics | |
|---|---|
| Market cap | NZ$320.89m |
| Earnings (TTM) | NZ$10.92m |
| Revenue (TTM) | NZ$174.51m |
30.1x
P/E Ratio1.9x
P/S RatioIs AFT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AFT income statement (TTM) | |
|---|---|
| Revenue | NZ$174.51m |
| Cost of Revenue | NZ$94.27m |
| Gross Profit | NZ$80.24m |
| Other Expenses | NZ$69.32m |
| Earnings | NZ$10.92m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 45.98% |
| Net Profit Margin | 6.26% |
| Debt/Equity Ratio | 49.8% |
How did AFT perform over the long term?
See historical performance and comparison